Lindsay Edwards is an internationally recognized leader at the interface of machine learning, computational biology, and drug discovery. Across both academia and industry, he has consistently advanced the translation of science into medicine using computational sciences. In his academic career in Australia and at King’s College London, he developed innovative computational approaches to human metabolism, hypoxia, and respiratory physiology. His teams pioneered methods for modelling metabolic and transcriptomic data, applying these to diverse clinical contexts including respiratory disease, diabetes, hypertension, Parkinson's disease, and critical illness. In industry, Lindsay founded one of the first pharmaceutical data science divisions at GSK, embedding machine learning and data science into every stage of the discovery pipeline. As CTO of Relation Therapeutics, he has raised over $200M, creating one of the most significant TechBio companies rooted in scientific translation (including forging a landmark platform multi billion dollar collaboration with GSK). His role on the Scientific Advisory Board of the Schmidt Center at the Broad Institute of MIT and Harvard further reflects his international collaborative reach, engaging with leading global scientists at the intersection of AI and life sciences. His publication record—over 40 papers in top biomedical journals (NEJM, JAMA, PNAS) and premier AI/ML venues (NeurIPS, ICML, ICLR)—is exceptionally rare, demonstrating dual impact across medicine and computational science.